Carla Grandori
Carla Grandori is Founder and President and Scientific Director at Cure First. She was VP head of Functional Clinical Modeling and Functional Genomics, Tempus AI Inc at Tempus AI and Chief Executive Officer at SEngine Precision Medicine. She was Research Member at Fred Hutch and Director at University of Washington. She is Leader, MYC Pathway, at the TCGA Pan-Cancer Analysis Project and Steering Committee Member at the Cancer Target Discovery & Development (CTD²) Network.
Carla Grandori announces Cure First’s PARIS® test helped guide effective treatment for a hard-to-treat sarcoma patient
Carla Grandori shares that a patient with a hard-to-treat sarcoma responded to treatment chosen using Cure First's PARIS® functional drug sensitivity test, which measures how a patient’s living tumor cells react to many drugs to help guide oncologists’ treatment decisions.
Organizations
See all 8-
Cure First Founder and President and Scientific Director 2025–present, Scientific Director 2014–present, President 2012–2025 · current
-
Tempus AI VP head of Functional Clinical Modeling and Functional Genomics, Tempus AI Inc 2023–2024 · past
-
SEngine Precision Medicine Chief Executive Officer 2015–2023 · past
Education
-
Massachusetts Institute of Technology Post-doctoral fellow, Cell/Cellular and Molecular Biology · 1989–1991
-
The Rockefeller University Doctor of Philosophy - PhD, Biochemistry and Molecular Biology · 1984–1990
-
Sapienza Università di Roma Doctor of Medicine - MD · 1976–1982